|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
The Challenges of Manufacturing Nanoparticles through Media Milling
Nanoparticles are gaining the pharmaceutical industry’s attention as research and practical experience demonstrate their many uses. Among other applications, nanoparticles have proven suitable for anticancer medications and microarray platforms for genomics and proteomics. The oral, parenteral, transdermal, transmucosal, ocular, and pulmonary drug-delivery routes can effectively use nanoparticles, and implants can incorporate these particles, too. In a 2007 study, research firm Freedonia Group concluded that demand for nanotech-based medical supplies and devices in the US will exceed a value of $110 billion by 2016.
Creating nanoparticles by media milling
Fine-bead mills are popular because of their simplicity and scalability. These machines are less expensive than alternative technologies (e.g., precipitation process techniques) and are often used in conjunction with plasma-gas process techniques. With the proper stabilizing agents, bead mills efficiently disperse output to discrete, submicrometer particle-size, stable dispersion (see Figure 1).
In bead mills, impact and shearing forces between moving beads grind suspended solid particles. The agitator shaft within the machine’s stator housing transmits kinetic energy to the grinding media.
Stress intensity and the number of contact points are the main factors that determine particle fineness. Stress intensity is influenced by the kinetic energy in the grinding beads. To produce a fine particle-size distribution, a process must have a high number of contact points. The smaller the grinding media, the more contact points touch the product. The rule of thumb is that particle size is equal to 1/1000 the size of the grinding media.
Achieving repeatable nanoparticle dispersions
As bead size decreases, the stand-off distance (i.e., the space between the beads) decreases. Reduced stand-off distance works as a filtering mechanism that holds back large agglomerates and breaks them apart. The stand-off distance is roughly 44 µm for 1-mm beads and about 2 µm for 0.05-mm beads. Using 70–125-µm beads yields a stand-off distance of about 4 µm. Mild dispersion uses small beads that provide a small stand-off distance, thus holding back large particles and shearing them apart to their primary (i.e., nonagglomerated) size. This technique ensures particle-size uniformity, reduces particle damage, and maintains productive work speeds.
The ideal mill has “plug flow,” which refers to a hydraulic condition where all the molecules or particles move through the bead mill at a uniform velocity. Plug flow thus maintains a uniform grind and residence time. On the other hand, turbulence (i.e., intermixing between the grinding zones) in bead mills usually means that particles mix at a broad velocity range and requires manufacturers to perform rapid multiple-pass operations to achieve a narrow particle-size distribution (see Figure 2).
Selecting suitable construction materials for the grinding media and chamber prevents batch contamination. Grinding-zone parts made entirely of yttria zirconia, a high-strength ceramic, offer metal- and contamination-free grinding. Grinding beads made of plastic, glass, ceramics such as aluminum oxide and zirconium oxide, steel, and tungsten carbide are also available.
With the right media milling equipment, researchers can cost-effectively create nanoparticles for drug delivery that are uniform and readily available. The advantages of working with nanoparticles will help reduce the time and cost of product development while improving drug performance and patient outcomes.
Harry Way is a technical director, and Chris Esterly is a pharmaceutical sales specialist at NETZSCH Fine Particle Technology.